Eli Lilly and Company (NYSE: LLY) has unveiled ambitious plans to bolster domestic pharmaceutical production by constructing four new manufacturing sites in the United States. This major initiative, announced on February 26, 2025, in Washington, D.C., marks the largest pharmaceutical manufacturing investment in U.S. history, bringing the company's total U.S. capital expansion commitments to over $50 billion since 2020.
The company has confirmed three of the new sites will concentrate on manufacturing active pharmaceutical ingredients (API), reshore critical capabilities for small molecule chemical synthesis, and enhance its supply chain. The fourth site will expand Lilly's global parenteral manufacturing network to support future injectable therapies.
David A. Ricks, Lilly's chair and CEO, expressed optimism, stating, "Our commitment to domestic manufacturing will not only benefit American families but also increase exports of medicines made in the U.S.A." Ricks emphasized the company's strategic position to meet anticipated demand for safe, high-quality, FDA-approved medicines.
The development of these four sites is expected to create more than 3,000 high-wage jobs for skilled workers, including engineers, scientists, and lab technicians. Additionally, nearly 10,000 construction jobs are anticipated during the sites' development.
Edgardo Hernandez, executive vice president and president of Lilly Manufacturing Operations, highlighted the company's investment in state-of-the-art manufacturing infrastructure to support next-generation modalities like small molecules and nucleic acid therapies. "We are not just building facilities; we are creating a future where American innovation leads the world in pharmaceutical manufacturing," Hernandez stated.
These new sites are anticipated to contribute significantly to selected communities, with expected benefits including increased local spending, tax revenue, economic diversification, improved infrastructure, population growth, and enhanced training and development opportunities.
Ricks also noted the importance of the Tax Cuts and Jobs Act legislation from 2017, highlighting its role in supporting Lilly's domestic manufacturing investments. He emphasized the need for these policies to continue, as they are vital to sparking further economic growth and job creation.
Since 2020, Lilly's domestic capital expansion commitments have included new sites in North Carolina and Indiana, as well as expansions and updates to existing facilities in Indianapolis. The company's previous commitments amounted to $23 billion, and with the new announcement, the total has now surpassed $50 billion.
The company is currently in negotiations with several states regarding site locations and invites further interest by March 12, 2025. Lilly expects to announce all four future site locations in 2025, with facilities anticipated to begin medicine production within five years.
Lilly is dedicated to turning science into healing and improving lives globally. With nearly 150 years of pioneering life-changing discoveries, Lilly's medicines help tens of millions of people worldwide. The company is committed to addressing significant health challenges, including redefining diabetes care, treating obesity, and advancing Alzheimer's disease treatment. For more information, visit Lilly.com.
For further details on the company's manufacturing plans, visit www.lilly.com/manufacturing-2025.
